{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:26:18Z","timestamp":1782444378648,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ijrobp.2023.06.076","type":"journal-article","created":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T08:00:36Z","timestamp":1689494436000},"page":"1262-1270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial"],"prefix":"10.1016","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3369-8567","authenticated-orcid":false,"given":"Meridith L.","family":"Balbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent N.","family":"Rexer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana G.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Niermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corbin R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Bapsi","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.06.076_bib0001","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0002","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0004","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0005","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM199605233342102","article-title":"The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer","volume":"334","author":"Recht","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0006","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2005.04.032","article-title":"Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial","volume":"23","author":"Bellon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3747\/co.21.2043","article-title":"Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?","volume":"22","author":"Mandilaras","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0008","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ijrobp.2017.08.002","article-title":"Neoadjuvant chemoradiation in the treatment of locally advanced breast cancer","volume":"99","author":"Chakravarthy","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0009","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/j.clbc.2020.04.014","article-title":"Comment on \u201cCombining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: feasibility, safety, and toxicity.\u201d","volume":"20","author":"De Santis","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0010","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","article-title":"Potential regional differences for the tolerability profiles of fluoropyrimidines","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0011","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1016\/j.ejca.2010.07.009","article-title":"First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial","volume":"46","author":"Kaufmann","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3816\/CBC.2007.n.050","article-title":"Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer","volume":"7","author":"Rossi","year":"2007","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-016-3756-5","article-title":"A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: A systematic review and meta-analysis","volume":"156","author":"Nishijima","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0014","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41523-017-0029-3","article-title":"CREATE-X a role for capecitabine in early-stage breast cancer: An analysis of available data","volume":"3","author":"Zujewski","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ncponc1240","article-title":"Capecitabine: Have we got the dose right?","volume":"6","author":"Midgley","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0016","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2020.02.010","article-title":"Combining adjuvant radiotherapy with capecitabine in chemotherapy-resistant breast cancer: Feasibility, safety, and toxicity","volume":"20","author":"Sherry","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/01.coc.0000245475.41324.6d","article-title":"A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer","volume":"30","author":"Gaui","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0018","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11604-010-0537-7","article-title":"Full-dose capecitabine with local radiotherapy: One of the treatment options for inoperable T4 breast cancer","volume":"29","author":"Hirowatari","year":"2011","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0019","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1748-717X-3-28","article-title":"Reirradiation of recurrent breast cancer with and without concurrent chemotherapy","volume":"3","author":"W\u00fcrschmidt","year":"2008","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2005.03.006","article-title":"Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse","volume":"15","author":"Hikino","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0021","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","article-title":"A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer","volume":"99","author":"Woodward","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0022","first-page":"67","article-title":"Quantification of patient-reported outcome measures of radiation-induced skin reactions for use in clinical trial design","volume":"25","author":"Russell","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0023","first-page":"217","volume":"2","author":"Hays","year":"1993","journal-title":"The RAND 36-Item Health Survey 1.0. Health Econ"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0024","series-title":"SF-36 Physical and Mental Health Summary Scales. A User\u2019s Manual","author":"Ware","year":"1994"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0026","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.adro.2016.01.003","article-title":"A prospective study of quality of life in breast cancer patients undergoing radiation therapy","volume":"1","author":"Xiao","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0028","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.breast.2019.09.009","article-title":"A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis","volume":"50","author":"Lam","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0029","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0030","unstructured":"Genentech. Full prescribing information: Xeloda. Available at: https:\/\/www.gene.com\/download\/pdf\/xeloda_prescribing.pdf. Accessed June 1, 2023"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.738851","article-title":"Risk factors related to acute radiation dermatitis in breast cancer patients after radiotherapy: A systematic review and meta-analysis","volume":"11","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0032","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0033","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa2112651","article-title":"Pembrolizumab in early triple-negative breast cancer. Reply","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0034","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clbc.2021.03.007","article-title":"Advances in combining radiation and immunotherapy in breast cancer","volume":"21","author":"Nguyen","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-022-00404-2","article-title":"Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +\/- trastuzumab in patients with breast cancer brain metastases","volume":"8","author":"Page","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0036","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0037","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0038","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clbc.2020.01.012","article-title":"A phase II study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer","volume":"20","author":"Barroso-Sousa","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0039","unstructured":"Pusztai L. Testing MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT02954874?term=NCT02954874&rank=1. Accessed June 1, 2023."},{"key":"10.1016\/j.ijrobp.2023.06.076_bib0040","unstructured":"Tredan O. Evaluate the clinical benefit of a post-operative treatment associating radiotherapy + nivolumab + ipilimumab versus radiotherapy + capecitabine for triple negative breast cancer patients with residual disease (breastimmune03). Available at: https:\/\/clinicaltrials.gov\/study\/NCT03818685?term=NCT03818685&rank=1. Accessed June 1, 2023."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162302196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162302196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:14:35Z","timestamp":1759745675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162302196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S036030162302196X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.076","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}